泽德曼与济川药业达成泽立美乳膏中国独家商业化合作

Group 1 - Shanghai Zedman Pharmaceutical Technology Co., Ltd. has signed an agreement with Jichuan Pharmaceutical Co., Ltd. for exclusive commercialization rights of Zeli Mei in China, excluding Hong Kong, Macau, and Taiwan [1] - Zedman will receive a maximum of 190 million yuan in upfront and milestone payments, including a maximum of 125 million yuan upfront and 65 million yuan for research milestones [1] - This collaboration marks a significant milestone in Zedman's market expansion and is a strategic move for resource complementarity and mutual benefits [1] Group 2 - Zeli Mei (Bimodamide Cream) is an innovative non-hormonal drug developed by Zedman, approved for treating eczema in children over 2 years old and adults, representing the first AhR modulator for this indication [2] - The drug works by suppressing inflammation, repairing skin barriers, regulating microbiota, and combating oxidative stress, addressing clinical pain points of traditional treatments [2] - Zedman’s CEO emphasized the importance of this partnership for maximizing the innovative value of Zeli Mei and accelerating its market promotion and clinical application in China [2] Group 3 - Jichuan Pharmaceutical's General Manager highlighted that this collaboration strengthens their product layout in pediatric and dermatological treatments, filling a clinical gap for young patients with eczema [2] - The partnership aims to leverage Jichuan's established sales network and specialized academic promotion team to expedite Zeli Mei's market entry and clinical adoption [2] - This initiative will enhance Jichuan's product matrix in pediatrics and dermatology, contributing to the development of skin health for children and adults in China [2]